BRIEF-Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test
April 27 Myriad Genetics Inc:
* Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment
* Says financial terms of deal were not disclosed.
* Myriad genetics inc- under deal,myriad will submit supplementary premarket approval application for bracanalysis cdx to include rubraca Source text for Eikon: Further company coverage:
ChargePoint secures $43 million in funding led by Siemens
SAN FRANCISCO, June 28 Electric vehicle charging station maker ChargePoint Inc said on Wednesday it had secured $43 million in financing led by German engineering group Siemens AG, bringing to a close the U.S. company's latest funding round at $125 million.
UK car output falls 10 pct in May ahead of new models
LONDON, June 29 British car production fell 9.7 percent in May as some major manufacturers reached the end of older product lines and prepared to begin building newer models, an industry body said on Thursday.